What diseases is Platinib mainly used to treat?

Pralsetinib is a highly selective RET tyrosine kinase inhibitor. It is mainly used to treat patients with solid tumors carrying RET gene fusions or mutations. It is especially widely used in targeted therapy of lung cancer and thyroid cancer. The most common indications include RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid carcinoma (MTC), and other RET fusion-positive thyroid cancer subtypes.

RET fusion-positive NSCLC is a rare but clinically unique subtype of lung cancer, accounting for approximately 1-2% of non-small cell lung cancer patients. Most of these patients are non-smokers or light smokers, are relatively young, and have limited effects of traditional chemotherapy or immunotherapy. By selectively inhibiting the activity of RET kinase and blocking its signaling pathway that drives the growth and spread of cancer cells, Platinib significantly improves progression-free survival and objective response rate. Some patients even experience durable complete response. Clinical research data shows that its ORR (objective response rate) can exceed 60%.

In the field of thyroid cancer, platinib is mainly used to treat patients with advanced medullary thyroid cancerRET mutations. MTC is a rare tumor originating from thyroid parafollicular cells, and approximately 25% of cases have RET gene mutations. Especially for patients who have failed systemic therapy or progressed after radiotherapy, platinib provides a new treatment option. In addition, platinib has also shown some clinical activity in some patients with breast, colorectal or pancreatic cancer who have been found to have RET fusions through genetic testing, although these are still in the research stage.

Overall, Platinib isan important breakthrough in the precision treatment of patients with RET fusion or mutation-positive patients, and is expected to be expanded to more solid tumor areas in the future. With the popularization of genetic testing, RET targeted therapy will also unleash its potential in more patients, pushing tumor treatment into a new era of more individualization and targeting.

Reference: https://gavreto.com/